EUVIMEDEUVIMED entdecken
Crossref

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy

Yan Xu, Xiaoge Zhang, Xiao Han, Hanwei Huang, Chaoyang Meng, Yinxian Yang, Tao Sheng, En Ren, Jiaqi Shi, Kaixin He, Dong Cen, Peng Zhao und 7 weitere

Cell · 2026-02 · 189 (3) · 872-886.e23

DOI: 10.1016/j.cell.2025.11.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-02. Verfasst von Yan Xu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems, School of …. Hauptthemen laut MEDLINE: Mast Cells, Immunotherapy, Drug Delivery Systems, Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell-mediated drug-delivery systems have garnered significant attention for their potential to boost therapeutic efficacy in cancer treatment. Here, we engineered immunoglobulin E (IgE)-sensitized mast cells (IgE-MCs) to achieve antigen-guided delivery of oncolytic adenoviruses (OVs) and local immune activation. By harnessing tumor-specific antigens as allergens, IgE-MCs accumulated at antigen-positive tumors, enabling targeted OV delivery and releasing chemokines and inflammatory mediators that remodeled the tumor microenvironment. IgE-MCs encapsulating OVs induced robust anticancer immune responses and inhibited tumor growth in several murine models. Of note, in a humanized human epidermal growth factor receptor-2 (HER2)-positive patient-derived xenograft model, human MCs armed with anti-HER2 IgE and loaded with OVs increased intratumoral T cell responses and reduced tumor growth, demonstrating feasibility in a clinically relevant setting and supporting patient-specific IgE selection. Together, our study highlights the translational promise of IgE-MCs as an antigen-specific delivery platform for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsImmunotherapyDrug Delivery SystemsNeoplasmsAnimalsHumansMiceImmunoglobulin ETumor MicroenvironmentFemaleCell Line, TumorAdenoviridaeErb-b2 Receptor Tyrosine KinasesOncolytic VirusesOncolytic VirotherapyXenograft Model Antitumor Assays

Stichwörter der Autor:innen

cancer immunotherapycell therapycell-drug conjugatedrug deliverymast cellsoncolytic adenoviruses

Substanzen

Immunoglobulin EErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, Zhejiang, China; Liang…
  • Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA.
  • Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110102, Liaoning, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China.
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, Zhejiang, China; Jinhu…

Förderung

  • Zhejiang Province Natural Science Foundation
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Y., Zhang, X., Han, X., Huang, H., Meng, C., Yang, Y., Sheng, T., Ren, E., Shi, J., He, K., Cen, D., Zhao, P., Fang, W., Li, H., Zhang, Y., Cai, X., Liu, F., Yu, J., & Gu, Z. (2026). Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell, 189(3), 872-886.e23. https://doi.org/10.1016/j.cell.2025.11.015

Vancouver

Xu Y, Zhang X, Han X, Huang H, Meng C, Yang Y, et al. Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell. 2026;189(3):872-886.e23. doi:10.1016/j.cell.2025.11.015

BibTeX
@article{Xu2026,
  author = {Xu, Yan and Zhang, Xiaoge and Han, Xiao and Huang, Hanwei and Meng, Chaoyang and Yang, Yinxian and Sheng, Tao and Ren, En and Shi, Jiaqi and He, Kaixin and Cen, Dong and Zhao, Peng and Fang, Weijia and Li, Hongjun and Zhang, Yuqi and Cai, Xiujun and Liu, Funan and Yu, Jicheng and Gu, Zhen},
  title = {Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {3},
  pages = {872--886.e23},
  doi = {10.1016/j.cell.2025.11.015}
}
Kostenlos starten →